nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.09.2013 | Original Paper

Relative and disease-free survival for breast cancer in relation to subtype: a population-based study

verfasst von: Pamela Minicozzi, Francesca Bella, Angela Toss, Adriano Giacomin, Mario Fusco, Maurizio Zarcone, Rosario Tumino, Fabio Falcini, Rosaria Cesaraccio, Giuseppa Candela, Francesco La Rosa, Massimo Federico, Milena Sant

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

No population-based study has investigated breast cancer (BC) subtypes defined by including Ki67. The aim of this study was to evaluate the relative proportions of immunohistochemical subtypes and differences in relative and disease-free survival between subtypes, in relation to patient and other cancer characteristics in Italian BC patient.

Methods

Information on estrogen, progesterone, human epidermal growth factor (HER2), Ki67, and relapses was obtained for 3,381 cases, sampled randomly and anonymously from cases diagnosed in 2003–2005 in nine Italian cancer registries. Relative excess risks (RERs) of death and risks of relapse 5 years after diagnosis were estimated.

Results

Luminal A cancers were 42 % of the total, luminal B 27 %, luminal-HER2 14 %, triple-negative 11 %, and HER2-enriched 7 %. For non-metastatic (3,302) cases, 4 and 7 % developed locoregional and distant metastases, respectively. RERs of death and risks of relapse were significantly greater for all cancer subtypes than luminal A, particularly for triple-negative and HER2-enriched cancers, which were more frequent in women <40 years.

Conclusions

Our population-based findings confirm that subtype is an independent prognostic factor for BC. Triple-negative and HER2-enriched subtypes would benefit from the development and wide application, respectively, of targeted treatments, which would also improve survival for younger patients.

Agresti A (2002) Categorical data analysis, 2nd edn. John Wiley & Sons, New YorkCrossRef

Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjällskog ML, Blomqvist C (2007) Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 51:491–498PubMedCrossRef

AIRTUM (2013) Database of Italian Association of Cancer Registries. http://www.registri-tumori.it/cms/en/node/2484. Accessed 13 May 2013

AIRTUM Working Group (2011) Italian cancer figures, report 2011: survival of cancer patients in Italy. Epidemiol Prev 35:1–200

AIRTUM Working Group, Crocetti E, Buzzoni C (2009) New incidence and mortality data 2003–2005. Epidemiol e Prev 33:e1–3, e5–26

Allemani C, Sant M, Berrino F, Aareleid T, Chaplain G, Coebergh JW, Colonna M, Contiero P, Danzon A, Federico M, Gafà L, Grosclaude P, Hédelin G, Macè-Lesech J, Garcia CM, Paci E, Raverdy N, Tretarre B, Williams EM (2004) Prognostic value of morphology and hormone receptor status in breast cancer—a population-based study. Br J Cancer 91:1263–1268PubMedCrossRef

Bertucci F, Birnbaum D (2008) Reasons for breast cancer heterogeneity. J Biol 7:6. doi:10.1186/jbiol67 PubMedCrossRef

Boyle P (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23:vi7–vi12PubMedCrossRef

Brouckaert O, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Paridaens R, Christiaens MR, Floris G, Moerman P, Van Limbergen E, Peeters S, Weltens C, Vergote I, Neven P (2012) Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol 23:2578–2584PubMedCrossRef

Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, Biancalani M, Zappa M (2011) Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Pathol Oncol Res 17:753–758. doi:10.1007/s12253-011-9381-z PubMedCrossRef

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef

Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750. doi:10.1093/jnci/djp082 PubMedCrossRef

Dickman PW, Sloggett A, Hills M, Hakulinen T (2004) Regression models for relative survival. Stat Med 23:51–64PubMedCrossRef

Ederer F, Heise H (1959) Instructions to IBM 650 Programmers in processing survival computations. Methodological note No. 10, End Results Evaluation Section. National Cancer Institute, Bethesda, MD

EUROCARE (2013) Survival of cancer patients in Europe. http://www.eurocare.it. Accessed 13 May 2013

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A (2013) Prognostic value of breast cancer subtypes, ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast J 19:22–30. doi:10.1111/tbj.12059 PubMedCrossRef

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2008) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917. doi:10.1002/ijc.25516 CrossRef

Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin LH, Parkin MD, Whelan S (2000) International classification of disease for oncology (ICD-O), 3rd edn. World Health Organization, Geneva

García Fernández A, Giménez N, Fraile M, González S, Chabrera C, Torras M, González C, Salas A, Barco I, Cirera L, Cambra MJ, Veloso E, Pessarrodona A (2012) Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010. Breast 21:366–373PubMedCrossRef

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn H-J, Panel members (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747. doi:10.1093/annonc/mdr304 PubMedCrossRef

Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Beretta GD, Caffo O, Caroti C, Crinò L, De Laurentiis M, Dinota A, Di Vito F, Gebbia V, Giustini L, Graiff C, Guida M, Lelli G, Lombardo M, Muggiano A, Puglisi F, Romito S, Salvagno L, Tagliaferri P, Terzoli E, Venturini M, AIOM Working Group Interaction with Regional Sections (2007–2009) (2010) Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society of Medical Oncology (AIOM). Tumori 96:1010–1015PubMed

Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF (2012) Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev 21:1848–1855. doi:10.1158/1055-9965.EPI-12-0474 PubMedCrossRef

Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef

Kataja V, Castiglione M, ESMO Guidelines Working Group (2009) Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:10–14. doi:10.1093/annonc/mdp114 PubMedCrossRef

Kneubil MC, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M (2013) Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. Eur J Surg Oncol 39:260–265. doi:10.1016/j.ejso.2012 PubMedCrossRef

Pathmanathan N, Provan PJ, Mahajan H, Hall G, Byth K, Bilous AM, Balleine RL (2012) Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing. Breast 21:724–729. doi:10.1016/j.breast.2012.09.001 PubMedCrossRef

Perou CM, Sorlie T, Elsen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684PubMedCrossRef

Sanpaolo P, Barbieri V, Genovesi D (2011) Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Eur J Surg Oncol 37:876–882. doi:10.1016/j.ejso.2011.07.001 PubMedCrossRef

Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R, EUROCARE Working Group (2009) EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer 45:931–991. doi:10.1016/j.ejca.2008.11.018 PubMedCrossRef

Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ, HERA study team (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36PubMedCrossRef

Sobin LH, Wittekind CH (2002) Breast Tumours. In: Sobin LH, Wittekind CH (eds) Classification of malignant tumours, 6th edn. Wiley-Liss, Geneva, pp 131–142

Spitale A, Mazzola P, Mazzucchelli L, Bordoni A (2009) Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 20:628–635. doi:10.1093/annonc/mdn675 PubMedCrossRef

StataCorp (2011) Stata statistical software: release 12. StataCorp LP, College Station, TX

Tawfik O, Davis K, Kimler BF, Davis MK, Hull S, Fan F, Khan QJ, O’Dea AP, Thomas P (2010) Clinicopathological characteristics of triple-negative invasive mammary carcinomas in African-American versus Caucasian women. Ann Clin Lab Sci 40:315–323PubMed

Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212–7220PubMedCrossRef

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846–3852PubMedCrossRef

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691. doi:10.1200/JCO.2009.24.9284 PubMedCrossRef

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology, College of American Pathologists (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRef

Zarcone M, Amodio R, Campisi I, Cusimano R, Dolcemascolo C, Miceli V, Traina A, Macaluso M (2009) Application of a new classification to a breast tumor series from a population-based cancer registry: demographic, clinical, and prognostic features of incident cases, Palermo Province, 2002–2004. Ann N Y Acad Sci 1155:222–226. doi:10.1111/j.1749-6632.2008.03693.x PubMedCrossRef

Titel: Relative and disease-free survival for breast cancer in relation to subtype: a population-based study
verfasst von: Pamela Minicozzi
Francesca Bella
Angela Toss
Adriano Giacomin
Mario Fusco
Maurizio Zarcone
Rosario Tumino
Fabio Falcini
Rosaria Cesaraccio
Giuseppa Candela
Francesco La Rosa
Massimo Federico
Milena Sant
Publikationsdatum: 01.09.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1478-1

Springer Medizin

Relative and disease-free survival for breast cancer in relation to subtype: a population-based study